Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Mivebresib

Alternative Names: mivebresib, abbv-075
Latest Update: 2024-05-15
Latest Update Note: PubMed Publication

Product Description

Mivebresib is an inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, mivebresib binds to the acetyl-lysine binding site of BRD-containing protein(s), thereby preventing the interaction between those proteins and acetylated histones. This disrupts chromatin remodeling, prevents the expression of certain growth-promoting genes, and leads to an inhibition of cell growth in susceptible tumors. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Mivebresib)

Mechanisms of Action: BET Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Breast Cancer|Lymphoma, Non-Hodgkin|Non-Small-Cell Lung Cancer|Prostate Cancer|Acute Myeloid Leukemia|Multiple Myeloma|Myelofibrosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
M20-248

P1

Terminated

Myelofibrosis

2023-07-28

21%
M14-546

P1

Completed

Acute Myeloid Leukemia|Lymphoma, Non-Hodgkin|Non-Small-Cell Lung Cancer|Multiple Myeloma|Prostate Cancer|Breast Cancer

2019-07-05

32%

Recent News Events

Date

Type

Title

05/15/2024

PubMed

 MYC family amplification dictates sensitivity to BET bromodomain protein inhibitor Mivebresib (ABBV-075) in small-cell lung cancer.

03/11/2024

PubMed

 Therapeutic Potential of Bromodomain and Extra-Terminal Domain Inhibitors for Synovial Sarcoma Cells.

12/01/2023

PubMed

 Epigenetic Cooperativity as a Therapeutic Vulnerability in Cancer.

11/21/2019

News Article

 AbbVie to Present Latest Clinical Research in the Treatment of Leukemias, Lymphomas and Other Blood Cancers at 2019 ASH Annual Meeting

05/30/2019

News Article

 AbbVie Presents Results from Several Studies and Clinical Trials Investigating Medicines Across More than 15 Cancers at the 2019 ASCO and EHA Meetings

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions